Back to list

Immunai

Developer of an immune system technology designed to provide treatments for oncology and auto-immune disorders.
Discovery Tools (Healthcare) 📍 New York, NY Founded 2018
Current Valuation
$960M
as of 2021-Q4
PRIVATE
Developer of an immune system technology designed to provide treatments for oncology and auto-immune disorders.

Company Profile

Founded
2018
HQ
New York, NY
Employees
180
Total Raised
$583.52M
Last Round
Series C — $204M (Dec 2021)
IPO Status
private

Fundraising Status

Series C · $204M · 4y 8mo ago
privateTotal raised $583.52M

Secondary Market

Implied price / share
$127.25
Last round price / share
$186.34
vs last round
-31.7%
Open interest
1
Last round price vs secondary price
Last round vs current secondary price per share$186Last round$127Current
Secondary price return by period
Secondary market period returns3-month-9.1%6-month-9.1%1-year-9.1%All-time-9.1%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series C$204MDec 2021$960M
Machine LearningArtificial IntelligenceBiotechnologyTherapeuticsAnalytics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q4. Refreshed quarterly.